Prof. Dr. Ahmet Dirican· @dr_dirican · X·· 2 days agoScore70
Body
#ESMO26 | Impressive results with a next-generation bispecific ADC!
Phase III PANKU-Breast01: EGFR×HER3-targeting iza-bren improved median PFS in HR+/HER2− metastatic breast cancer (8.2 vs 4.0 months; HR 0.41).
However, grade ≥3 treatment-related AEs reached 85.3%.
Key questions: Do ESR1, PIK3CA, or PTEN alterations influence response? What is the impact of prior ADC exposure?
#ESMO26 #BreastCancer #ADC @myESMO @oncodaily @OncoAlert
149 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Prof. Dr. Ahmet Dirican · x.com